Company Overview and News
The U.S-China trade spat has started taking its toll on tech companies, particularly chipmaker stocks. On Jun 19, President Donald Trump asked the United States Trade Representative to identify Chinese goods worth $200 billion for additional tariffs. Consequently, China too said that it would have to take comprehensive measures to counter U.S. trade moves.
SWKS QRVO AAPL AVGO NVDA LITE BRCM QCOM INTC
Chicago, IL – June 20, 2018 – Zacks Equity Research highlights Align Technology (ALGN - Free Report) as the Bull of the Day and Qorvo (QRVO - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Oracle Corp. (ORCL - Free Report) and FedEx (FDX - Free Report) .
LOPE QRVO ALGN SCVL OCLCF HEAR FDX DLA AMWD ORCL
The Internet of Things (IoT) is not longer some strange, unknowable concept. Instead it has integrated itself almost seamlessly into consumer products.
QRVO FIT GE F GEC NXPI GOOG SWKS WHR AMZN NDAQ GOOGL GM.WS.A GM.WS.B AAPL GM.WS.C GNE GM QCOM GM.WSB
In case you are still holding on to shares of Qorvo, Inc. (QRVO - Free Report) in your portfolio, it’s high time to get rid of the stock. The odds in favor of an upside in the near term are slim. The company has been witnessing downward revisions and has weak fundamentals. Customer concentration from Apple (AAPL - Free Report) is another major concern. Downward Estimate Revisions Analysts have become increasingly bearish on the stock in the past couple of months with all estimates moving south and no movement in the opposite direction for the ongoing quarter.
QRVO AAPL WDC
Qorvo, Inc. (QRVO - Free Report) made a cash Tender Offer for the redemption of any or all of its 6.75% Senior Notes and 7.00% Senior Notes worth up to $150 million. The notes are due in 2023 and 2025, respectively. Notably, these are popularly known as “the Notes.” The offer is subject to certain terms and conditions.
QRVO MU ENSG AAPL WDC
Qorvo, Inc. (QRVO - Free Report) recently launched five new 5G products. The enhanced 5G infrastructure solutions portfolio now comprises two new integrated front end modules (FEMs) — QPB9329 & QPB9319 — and a wideband driver amplifier — QPA9120. The other two new 2-stage power amplifiers are QPA4501 & QPA3506. The small-sized, highly integrated and efficient new FEMs support frequency bands ranging from 3GHz (gigahertz) to 39GHz.
QRVO MU AAPL WDC
GREENSBORO, N.C., June 12, 2018 (GLOBE NEWSWIRE) -- Qorvo® (Nasdaq:QRVO), a leading provider of innovative RF solutions that connect the world, today introduced five new power amplifiers and front end modules that further expand its portfolio of RF products for massive MIMO and 5G base stations. These highly integrated, efficient, small-size modules support all frequency bands used for pre-5G and 5G architectures, from 3GHz to 39GHz.
Apple’s (AAPL - Free Report) strategy of becoming self-reliant has had a detrimental effect on suppliers like Dialog Semiconductor (DLGNF - Free Report) . The iPhone-maker recently lowered its order for power-management chips (PMICs), of which Dialog is the primary supplier, by almost 30%. Apple’s decision to multi-source PMIC chips for one of its three new iPhone models, set to release in 2018, is expected to hurt Dialog’s top-line by 5%.
QRVO JNNDF AAPL CRUS 6740 DLGNF JPDYY INTC
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
as of ET